Should We Be Surprised That in the TiNivo-2 Trial, Tivozanib plus Nivolumab Is Negative When Compared to Tivozanib Monotherapy, After Progression on a Prior Immune Checkpoint Inhibitor?
TIVO-3 randomized phase 3 trial of tivozanib, vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor, CONTACT-03 phase 3 trial, TiNivo-2 trial.